% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Olar:120434,
author = {A. Olar and K. M. Wani and C. D. Wilson and G. Zadeh and F.
DeMonte and D. Jones$^*$ and S. Pfister$^*$ and E. P. Sulman
and K. D. Aldape},
title = {{G}lobal epigenetic profiling identifies methylation
subgroups associated with recurrence-free survival in
meningioma.},
journal = {Acta neuropathologica},
volume = {133},
number = {3},
issn = {1432-0533},
address = {Berlin},
publisher = {Springer},
reportid = {DKFZ-2017-00863},
pages = {431 - 444},
year = {2017},
abstract = {Meningioma is the most common primary brain tumor and
carries a substantial risk of local recurrence. Methylation
profiles of meningioma and their clinical implications are
not well understood. We hypothesized that aggressive
meningiomas have unique DNA methylation patterns that could
be used to better stratify patient management. Samples
(n = 140) were profiled using the Illumina
HumanMethylation450BeadChip. Unsupervised modeling on a
training set (n = 89) identified 2 molecular methylation
subgroups of meningioma (MM) with significantly different
recurrence-free survival (RFS) times between the groups: a
prognostically unfavorable subgroup (MM-UNFAV) and a
prognostically favorable subgroup (MM-FAV). This finding was
validated in the remaining 51 samples and led to a baseline
meningioma methylation classifier (bMMC) defined by 283 CpG
loci (283-bMMC). To further optimize a recurrence predictor,
probes subsumed within the baseline classifier were subject
to additional modeling using a similar training/validation
approach, leading to a 64-CpG loci meningioma methylation
predictor (64-MMP). After adjustment for relevant clinical
variables [WHO grade, mitotic index, Simpson grade, sex,
location, and copy number aberrations (CNAs)] multivariable
analyses for RFS showed that the baseline methylation
classifier was not significant (p = 0.0793). The
methylation predictor, however, was significantly associated
with tumor recurrence (p < 0.0001). CNAs were extracted
from the 450k intensity profiles. Tumor samples in the
MM-UNFAV subgroup showed an overall higher proportion of
CNAs compared to the MM-FAV subgroup tumors and the CNAs
were complex in nature. CNAs in the MM-UNFAV subgroup
included recurrent losses of 1p, 6q, 14q and 18q, and gain
of 1q, all of which were previously identified as indicators
of poor outcome. In conclusion, our analyses demonstrate
robust DNA methylation signatures in meningioma that
correlate with CNAs and stratify patients by recurrence
risk.},
cin = {B062 / L101},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28130639},
doi = {10.1007/s00401-017-1678-x},
url = {https://inrepo02.dkfz.de/record/120434},
}